Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-T Therapy (ANOC-001, ANOC-002, ANOC-003) in Metastatic or Locally Advanced PDAC
NCT07145450Phase 2Recruiting
- Sponsor
- Anocca
- Start
- Jul 2025
- Primary completion
- Apr 2030
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 4
01
Overview
Phase 2, open-label trial of ANOC-001, ANOC-002 and ANOC-003 in pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by Anocca. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events at 28 days and 5 more. Started Jul 2025; status: recruiting.
02
Drugs
ANOC-001ANOC-002ANOC-003
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07145450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145450.